Febuxostat Reduces Contrast-Induced Acute Kidney Injury in Stage 3 CKD
Patients with stage 3 chronic kidney disease are at increased risk for contrast-induced acute kidney injury.
Patients with stage 3 chronic kidney disease are at increased risk for contrast-induced acute kidney injury.
Given the widespread use of contrast medium in cardiovascular and other imaging, continued focus on preventing contrast-induced acute kidney injury is warranted.
Transient hypotension increases the risk for post-contrast acute kidney injury following computed tomography with contrast media, according to investigators.
Previous research suggested that allopurinol, a xanthine oxidase inhibitor, prevents the formation of oxygen-free radicals that may contribute to contrast nephropathy.
Gadavist® Imaging Bulk Package is supplied as 604.72mg/mL of gadobutrol in 30mL and 65mL multidose containers.
Radiologists and clinicians should weigh the relative benefits and risks of using IV contrast in patients with eGFRs less than 30 mL/min/1.73 m2, according to a consensus statement.
Withholding prehydration with sodium bicarbonate from patients with CKD stage 3 undergoing nonemergent contrast-enhanced computed tomography does not compromise renal safety, a study found.
The potential diagnostic harms of withholding group II gadolinium-based contrast agents may outweigh the risk of nephrogenic systemic fibrosis in advanced CKD patients, according to investigators.
The risk of post-contrast acute kidney injury increased with decreasing renal function.
No patient had a 25% or greater rise in serum creatinine 48 hours after receiving a median 13 mL of contrast for diagnostic coronary angiography, with an additional 13 mL for percutaneous coronary intervention.